Free tool
FAERS Monitor: Cresemba
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207501 or its brand name (Cresemba, Isavuconazonium Sulfate). Reports on generic versions are filed under their own applications.
Reports
3,844
Serious
2,685
70% of reports
Hospitalization
1,236
Death reported
770
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,094
- death344
- nausea190
- drug ineffective173
- febrile neutropenia151
- pyrexia150
- pneumonia142
- condition aggravated136
- fatigue127
- diarrhoea114
- dyspnoea109
- product use in unapproved indication106
- disease progression104
- drug interaction102
- vomiting101
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 57 |
| 2016 | 250 |
| 2017 | 575 |
| 2018 | 238 |
| 2019 | 269 |
| 2020 | 269 |
| 2021 | 208 |
| 2022 | 250 |
| 2023 | 253 |
| 2024 | 364 |
| 2025 | 520 |
| 2026 | 591 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,315 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 151 | 12.5 | 10.7 | 1,585 |
| off label useSignal | 1,094 | 6.8 | 6.5 | 5,682 |
| disease progressionSignal | 104 | 4.8 | 4.0 | 312 |
| drug interactionSignal | 102 | 3.5 | 2.9 | 183 |
| condition aggravatedSignal | 136 | 2.4 | 2.1 | 117 |
| pneumoniaSignal | 142 | 2.4 | 2.0 | 116 |
| pyrexiaSignal | 150 | 2.4 | 2.0 | 120 |
| product use in unapproved indicationSignal | 106 | 2.3 | 1.9 | 81 |
| deathSignal | 344 | 2.2 | 2.0 | 229 |
| nausea | 190 | 1.3 | 1.1 | 14 |
| vomiting | 101 | 1.2 | 1.0 | 3 |
| dyspnoea | 109 | 1.1 | 0.9 | 0 |
| diarrhoea | 114 | 1.0 | 0.8 | 0 |
| fatigue | 127 | 0.9 | 0.8 | 2 |
| drug ineffective | 173 | 0.7 | 0.6 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.